733 reports of this reaction
3.8% of all RIMEGEPANT SULFATE reports
#4 most reported adverse reaction
HEADACHE is the #4 most commonly reported adverse reaction for RIMEGEPANT SULFATE, manufactured by Pfizer Laboratories Div Pfizer Inc. There are 733 FDA adverse event reports linking RIMEGEPANT SULFATE to HEADACHE. This represents approximately 3.8% of all 19,247 adverse event reports for this drug.
Patients taking RIMEGEPANT SULFATE who experience headache should discuss this symptom with their healthcare provider to determine whether it may be related to their medication and what alternatives may be available.
HEADACHE is moderately reported among RIMEGEPANT SULFATE users, representing a notable but not dominant share of adverse events.
In addition to headache, the following adverse reactions have been reported for RIMEGEPANT SULFATE:
The following drugs have also been linked to headache in FDA adverse event reports:
HEADACHE has been reported as an adverse event in 733 FDA reports for RIMEGEPANT SULFATE. This does not prove causation, but indicates an association observed in post-market surveillance data.
HEADACHE accounts for approximately 3.8% of all adverse event reports for RIMEGEPANT SULFATE, making it a notable side effect.
If you experience headache while taking RIMEGEPANT SULFATE, contact your healthcare provider. They can evaluate whether the symptom is related to your medication and discuss potential adjustments to your treatment plan. Do not stop taking prescribed medication without consulting your doctor.